Literature DB >> 18064719

AAV-mediated knockdown of phospholamban leads to improved contractility and calcium handling in cardiomyocytes.

Lourdes M Andino1, Morihiko Takeda, Hideko Kasahara, Andrew Jakymiw, Barry J Byrne, Alfred S Lewin.   

Abstract

BACKGROUND: Reduced contractility due to dysregulation of intracellular calcium (Ca(2+)) is a common pathologic feature of chronic heart failure. Calcium stores in the sarcoplasmic reticulum play a major role in regulating cardiac contractility. Several animal models of heart failure have been treated by altering the regulation of the sarcoplamic reticulum ATPase through ablation or down-regulation of its inhibitor peptide, phospholamban (PLN).
METHODS: We have designed two small hairpin RNAs (shRNAs) to block the synthesis of PLN via RNA interference. These were tested in cell culture using a co-transfection assay and using adeno-associated virus (AAV)-mediated delivery to cardiomyocytes. Reverse-transcription polymerase chain reaction (RT-PCR) and Western blots were used to measure reduction in PLN mRNA and protein levels. Reduction of PLN was also documented by indirect immunofluorescence. Free cytosolic calcium and contractile properties of transduced cardiomyocytes was examined on fura-2-loaded cells. Direct cardiac injection was used to deliver AAV1-shRNAs to mice, and reduction of PLN was measured by indirect immunofluorescence.
RESULTS: Both siRNAs led to significant reduction of PLN RNA and protein levels in cultured cells. Down-regulation of PLN led to enhanced cell shortening and relaxation and to a decrease in the time constant of calcium decay, signs of improved contractility and calcium handling. In the hearts of AAV-infected mice, shRNA-transduced cells showed significant reduction in the level of PLN.
CONCLUSIONS: Our results suggest that AAV-delivered shRNAs mediated physiologically significant suppression of phospholamban that may be useful in combating the effects of chronic heart failure.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18064719     DOI: 10.1002/jgm.1131

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  15 in total

Review 1.  Endoplasmic-reticulum calcium depletion and disease.

Authors:  Djalila Mekahli; Geert Bultynck; Jan B Parys; Humbert De Smedt; Ludwig Missiaen
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-06-01       Impact factor: 10.005

Review 2.  Methods in cardiomyocyte isolation, culture, and gene transfer.

Authors:  William E Louch; Katherine A Sheehan; Beata M Wolska
Journal:  J Mol Cell Cardiol       Date:  2011-06-24       Impact factor: 5.000

3.  Phospholamban phosphorylation, mutation, and structural dynamics: a biophysical approach to understanding and treating cardiomyopathy.

Authors:  Naa-Adjeley D Ablorh; David D Thomas
Journal:  Biophys Rev       Date:  2015-01-21

4.  Alpha1 catalytic subunit of AMPK modulates contractile function of cardiomyocytes through phosphorylation of troponin I.

Authors:  Si Chen; Ping Zhu; Hui-Ming Guo; Raquel Sancho Solis; Yanqing Wang; Yina Ma; Jinli Wang; Junjie Gao; Ji-Mei Chen; Ying Ge; Jian Zhuang; Ji Li
Journal:  Life Sci       Date:  2014-01-19       Impact factor: 5.037

Review 5.  AAV vectors for cardiac gene transfer: experimental tools and clinical opportunities.

Authors:  Christina A Pacak; Barry J Byrne
Journal:  Mol Ther       Date:  2011-07-26       Impact factor: 11.454

6.  Cardiac gene transfer of short hairpin RNA directed against phospholamban effectively knocks down gene expression but causes cellular toxicity in canines.

Authors:  Lawrence T Bish; Meg M Sleeper; Caryn Reynolds; Jeffrey Gazzara; Elanor Withnall; Gretchen E Singletary; George Buchlis; Daniel Hui; Katherine A High; Guangping Gao; James M Wilson; H Lee Sweeney
Journal:  Hum Gene Ther       Date:  2011-06-08       Impact factor: 5.695

7.  Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy.

Authors:  Lennart Suckau; Henry Fechner; Elie Chemaly; Stefanie Krohn; Lahouaria Hadri; Jens Kockskämper; Dirk Westermann; Egbert Bisping; Hung Ly; Xiaomin Wang; Yoshiaki Kawase; Jiqiu Chen; Lifan Liang; Isaac Sipo; Roland Vetter; Stefan Weger; Jens Kurreck; Volker Erdmann; Carsten Tschope; Burkert Pieske; Djamel Lebeche; Heinz-Peter Schultheiss; Roger J Hajjar; Wolfgang C Poller
Journal:  Circulation       Date:  2009-02-23       Impact factor: 29.690

8.  Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat.

Authors:  Lawrence T Bish; Kevin Morine; Meg M Sleeper; Julio Sanmiguel; Di Wu; Guangping Gao; James M Wilson; H Lee Sweeney
Journal:  Hum Gene Ther       Date:  2008-12       Impact factor: 5.695

Review 9.  An emerging adeno-associated viral vector pipeline for cardiac gene therapy.

Authors:  Aravind Asokan; R Jude Samulski
Journal:  Hum Gene Ther       Date:  2013-11       Impact factor: 5.695

10.  Viral expression of a SERCA2a-activating PLB mutant improves calcium cycling and synchronicity in dilated cardiomyopathic hiPSC-CMs.

Authors:  Daniel R Stroik; Delaine K Ceholski; Philip A Bidwell; Justyna Mleczko; Paul F Thanel; Forum Kamdar; Joseph M Autry; Razvan L Cornea; David D Thomas
Journal:  J Mol Cell Cardiol       Date:  2019-11-18       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.